Related references
Note: Only part of the references are listed.The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
H. Blasco et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Natalia Guzior et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Donepezil plus propargylamine+8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease
Li Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Evidence for the Efficacy of Latrepirdine (Dimebon) Treatment for Improvement of Cognitive Function: A Meta-Analysis
Nieves Cano-Cuenca et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?
Ian R. Macdonald et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Multi-target Design Strategies in the Context of Alzheimer's Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces
Michela Rosini et al.
NEUROCHEMICAL RESEARCH (2014)
Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease
Paula M. Canas et al.
NEUROPHARMACOLOGY (2014)
Determination of binding points of methylene blue and cationic phenoxazine dyes on human butyrylcholinesterase
Zeynep Sezgin et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2013)
Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model
John W. Steele et al.
AUTOPHAGY (2013)
Effects of viscosity and osmotic stress on the reaction of human butyrylcholinesterase with cresyl saligenin phosphate, a toxicant related to aerotoxic syndrome: kinetic and molecular dynamics studies
Patrick Masson et al.
BIOCHEMICAL JOURNAL (2013)
Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors
Lyudmila G. Tsurkan et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2013)
Organophosphorus compound esterase profiles as predictors of therapeutic and toxic effects
Galina F. Makhaeva et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2013)
Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
W. J. Geldenhuys et al.
CURRENT MEDICINAL CHEMISTRY (2013)
From the Multifactorial Nature of Alzheimer's Disease to Multitarget Therapy: The Contribution of the Translational Approach
Laura Calza et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
M. Carmo Carreiras et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease
Abdelouahid Samadi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease
Chris G. Parsons et al.
NEUROTOXICITY RESEARCH (2013)
The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
S. Casey Laizure et al.
PHARMACOTHERAPY (2013)
Molecular modeling of butyrylcholinesterase inhibition by cresyl saligenin phosphate
S. V. Lushchekina et al.
RUSSIAN CHEMICAL BULLETIN (2013)
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases
P R Bharadwaj et al.
Translational Psychiatry (2013)
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
Salvatore Salomone et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease
Paul T. Francis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Combined QSAR studies of inhibitor properties of O-phosphorylated oximes toward serine esterases involved in neurotoxicity, drug metabolism and Alzheimer's disease
G. F. Makhaeva et al.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH (2012)
Cholinesterase inhibitors and memantine for symptomatic treatment of dementia
Joanne Rodda et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
Moussa B. H. Youdim
Experimental Neurobiology (2011)
Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants
Sultan Darvesh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Hani Atamna et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Methylene blue and Alzheimer's disease
Murat Oz et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
Agneta Nordberg et al.
CURRENT ALZHEIMER RESEARCH (2009)
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models
Makiko Yamashita et al.
FEBS LETTERS (2009)
Amyotrophic lateral sclerosis: A 40-year personal perspective
Andrew Eisen
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity
M. Weinstock et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Elliott J Mufson et al.
Expert Review of Neurotherapeutics (2008)
Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase
Sultan Darvesh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental alzheimer therapeutic, dihydrobenzodioxepine cymserine
Mohammad A. Kamal et al.
NEUROCHEMICAL RESEARCH (2008)
Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine
Sultan Darvesh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Rationale for combination therapy with galantamine and Memantine in Alzheimer's disease
George T. Grossberg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
RM Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Human carboxylesterase isozymes: Catalytic properties and rational drug design
Teruko Imai
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease
A Martinez et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
NH Greig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives
S Darvesh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Cholinesterase inhibitors used in the treatment of Alzheimer's disease the relationship between pharmacological effects and clinical efficacy
DG Wilkinson et al.
DRUGS & AGING (2004)
Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products
Y Nicolet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons
VV Grigor'ev et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2003)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
